Koers Coeptis Therapeutics, Inc. OTC Markets
Aandelen
COEP
US19207C1045
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 12,67 mln. 11,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,39 mln. | Nettowinst (verlies) 2025 * | -35 mln. -32,84 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,46
x | K/w-verhouding 2025 * |
-0,4
x | Werknemers | 6 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 67,46% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28-10-22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17-05-23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28-10-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 62 | 28-10-22 | |
Director/Board Member | 55 | 28-10-22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28-10-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,81% | 672 mld. | |
+24,08% | 550 mld. | |
-6,38% | 351 mld. | |
+14,94% | 317 mld. | |
+7,05% | 292 mld. | |
+3,26% | 211 mld. | |
+0,78% | 203 mld. | |
-10,47% | 144 mld. | |
-7,64% | 141 mld. |